All In Biotech

Drug Trial Radar · NCT06602531

Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults

A Phase 1, First-in-human, Randomized, Observer-blind, Parallel Design, Controlled, Dose Level and Schedule-finding Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of a Self-Amplifying mRNA Pandemic Influenza Vaccine (ARCT-2304) When Administered to Healthy Adults

Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 212 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

212

Actual

Start

Dec 10, 2024

Primary completion

Jun 13, 2025

Study completion Dec 5, 2025

Sponsor

Lead sponsor
Arcturus Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
Biomedical Advanced Research and Development Authority
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the safety and immune responses of three different dose levels a self-amplifying RNA pandemic influenza vaccine (ARCT-2304) in adults. The key objectives of the study are: * To evaluate safety and reactogenicity of different dose levels of the ARCT-2304 vaccine * To describe the Immune responses of different dose levels of the ARCT-2304 vaccine as measured by hemagglutination inhibition (HAI) and neuraminidase enzyme-linked lectin (ELLA) antibody responses Researchers will compare the results with licensed influenza vaccines to select the most optimal dose level and schedule for vaccine administration in terms of safety and immunogenicity for further development of the vaccine. Participants will receive 2 doses of the ARCT-2304 vaccine or 1 dose of licensed influenza vaccine and 1 dose of placebo. They will be asked: * to complete a daily diary for 7 days after each vaccination, answering questions how they have been feeling on that day. * to provide blood samples at each visit in the clinic * to comply with all study visits and procedures (e.g., be available for planned telephone contacts and unscheduled clinic visits, if required)

Conditions

  • Influenza, Human

Interventions

  • ARCT-2304Biological

    Each participant will receive 2-dose regimen intramuscular (IM) dose into the deltoid muscle.

  • Control vaccine younger adultsBiological

    Each participant will receive one intramuscular (IM) dose into the deltoid muscle.

  • Control vaccine older adultsBiological

    Each participant will receive one intramuscular (IM) dose into the deltoid muscle.

  • Placebo VaccineOther

    Each participant will receive one intramuscular (IM) dose into the deltoid muscle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Solicited Adverse Events (AEs) Within 7 Days After Each VaccinationTime frame: 7 days post each dose
  2. Number of Participants With Unsolicited AEs Within 28 Days After Each VaccinationTime frame: D1,29 Cohorts: up to Day 29 and up to Day 57 (28 days post each dose), D1,57 Cohorts: up to Day 29 and up to Day 85 (28 days post each dose)
  3. Number of Participants With Serious Adverse Events (SAEs), Medically Attended AEs (MAAEs), AEs of Special Interest (AESIs), and AEs Leading To Early Termination From Day 1 to 28 Days After Second VaccinationTime frame: D1,29 Cohorts: up to Day 57, D1,57 Cohorts: up to Day 85
  4. Geometric Mean Titer of Antibody Response to Hemagglutinin (HA) Glycoprotein Measured By Hemagglutinin Inhibition (HAI) AssayTime frame: D1,29 Cohorts: Day 1, Day 29 (28 days post dose 1), Day 36 (7 days post dose 2), and Day 57 (28 days post dose 2), D1,57 Cohorts: Day 1, Day 57 (56 days post dose 1), Day 64 (7 days post dose 2), and Day 85 (28 days post dose 2)
  5. Geometric Mean Titer of Antibody Response to Neuraminidase (NA) Glycoprotein Measured By Enzyme-linked Lectin Assay (ELLA)Time frame: D1,29 Cohorts: Day 1, Day 29 (28 days post dose 1), Day 36 (7 days post dose 2), and Day 57 (28 days post dose 2), D1,57 Cohorts: Day 1, Day 57 (56 days post dose 1), Day 64 (7 days post dose 2), and Day 85 (28 days post dose 2)
  6. Geometric Mean Fold Rise of Antibody Response to HA Glycoprotein Measured By HAI AssayTime frame: D1,29 Cohorts: Day 29 (28 days post dose 1), Day 36 (7 days post dose 2), and Day 57 (28 days post dose 2), D1,57 Cohorts: Day 57 (56 days post dose 1), Day 64 (7 days post dose 2), and Day 85 (28 days post dose 2)
  7. Geometric Mean Fold Rise of Antibody Response to NA Glycoprotein Measured By ELLATime frame: D1,29 Cohorts: Day 29 (28 days post dose 1), Day 36 (7 days post dose 2), and Day 57 (28 days post dose 2), D1,57 Cohorts: Day 57 (56 days post dose 1), Day 64 (7 days post dose 2), and Day 85 (28 days post dose 2)
  8. Percentage of Participants With Seroconversion of Antibody Response to HA Glycoprotein Measured By HAI AssayTime frame: D1,29 Cohorts: Day 29 (28 days post dose 1), Day 36 (7 days post dose 2), and Day 57 (28 days post dose 2), D1,57 Cohorts: Day 57 (56 days post dose 1), Day 64 (7 days post dose 2), and Day 85 (28 days post dose 2)
  9. Percentage of Participants With Seroconversion of Antibody Response to NA Glycoprotein Measured By ELLATime frame: D1,29 Cohorts: Day 29 (28 days post dose 1), Day 36 (7 days post dose 2), and Day 57 (28 days post dose 2), D1,57 Cohorts: Day 57 (56 days post dose 1), Day 64 (7 days post dose 2), and Day 85 (28 days post dose 2)
  10. Percentage of Participants With HAI Titers Above or Equal to Prespecified ThresholdsTime frame: D1,29 Cohorts: Day 57 (28 days post dose 2), D1,57 Cohorts: Day 85 (28 days post dose 2)
  11. Percentage of Participants With ELLA Titers Above or Equal to Prespecified ThresholdsTime frame: D1,29 Cohorts: Day 57 (28 days post dose 2), D1,57 Cohorts: Day 85 (28 days post dose 2)

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Velocity Clinical Research

    La Mesa, California

  • Velocity Clinical Research

    San Bernardino, California

  • Tekton Research

    Longmont, Colorado

  • CTI Clinical Research Center

    Cincinnati, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.